Literature DB >> 26972374

Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.

J Martins1, H Alexandrino2, R Oliveira3, M A Cipriano3, D Falcão1, L Ferreira4, R Martins5, M Serôdio4, M Martins5, J G Tralhão5, L Prado e Castro3, F Castro E Sousa5.   

Abstract

INTRODUCTION: Advances in neoadjuvant chemotherapy (NCT) have allowed surgical treatment in otherwise unresectable patients with colorectal liver metastases (CRLM). It is well known that NCT induces liver lesions such as sinusoidal obstruction syndrome (SOS) and steatohepatitis (SH). However, whether it affects postoperative morbidity remains controversial. The aim of this study was both to evaluate the impact of NCT on liver parenchyma and postoperative morbidity, and to identify preoperative predictive markers for liver injury. PATIENTS AND METHODS: Among 140 patients undergoing liver resection for CRLM between 2010 and 2013, 70 underwent systemic NCT. Liver function tests, pathology, postoperative morbidity and mortality were compared between the two groups.
RESULTS: Univariate analysis revealed NCT as a cause of sinusoidal dilation (p = 0.09), peliosis (p = 0.028) and moderate and severe SOS (p = 0.004) and bevacizumab as a protective agent against moderate and severe SOS (p = 0.045). Diabetic patients were identified as having a lower incidence of sinusoidal dilation (p = 0.034) and a higher incidence of steatosis (p = 0.003). Multivariate analysis confirmed sinusoidal dilation as an independent cause for morbidity (p = 0.02) and liver-specific complications (p = 0.016). Preoperative level of GGT was identified as predictive factor for moderate and severe SOS and peliosis (p < 0.001 and p = 0.004, respectively).
CONCLUSION: The administration of NCT induces SOS-lesions, but can be partially prevented by bevacizumab and diabetes. Sinusoidal dilation is associated with increased postoperative morbidity. Preoperative GGT levels can be useful to predict the presence of SOS.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colorectal neoplasms; Hepatectomy; Neoadjuvant therapy; Sinusoidal obstruction syndrome

Mesh:

Substances:

Year:  2016        PMID: 26972374     DOI: 10.1016/j.ejso.2016.02.017

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

1.  The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis.

Authors:  Li-Na Zhou; Chun-Xia Feng; Yan Zhang; Ping Li; Min Tang; Min-Bin Chen; Jun Jin
Journal:  J Gastrointest Oncol       Date:  2022-06

Review 2.  Chemotherapy-Induced Liver Injury in Patients with Colorectal Liver Metastases: Findings from MR Imaging.

Authors:  Francescamaria Donati; Dania Cioni; Salvatore Guarino; Maria Letizia Mazzeo; Emanuele Neri; Piero Boraschi
Journal:  Diagnostics (Basel)       Date:  2022-03-31

3.  Prognostic Factors After Hepatectomy for Gastric Adenocarcinoma Liver Metastases: Desmoplastic Growth Pattern as the Key to Improved Overall Survival.

Authors:  Maria José Temido; Rui Caetano Oliveira; Ricardo Martins; Marco Serôdio; Beatriz Costa; César Carvalho; Eva Santos; Luís Ferreira; Paulo Teixeira; Maria Augusta Cipriano; José Guilherme Tralhão; Henrique Alexandrino
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

4.  Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False.

Authors:  Marie Desjardin; Benjamin Bonhomme; Brigitte Le Bail; Serge Evrard; Véronique Brouste; Gregoire Desolneux; Marianne Fonck; Yves Bécouarn; Dominique Béchade
Journal:  Clin Med Insights Oncol       Date:  2019-01-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.